Read + Share
Maguire WF, Lee D, Weinstock C, Gao X, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for
Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2024;30:2011-2016.
PMID: 38441576
|
 |
|
Maguire WF, Lee D, Weinstock C, Gao X, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for
Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2024;30:2011-2016.
PMID: 38441576
|
|
|
|